VERU INC. - COMMON STOCK

Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

01 May 2024 08:30:37 By Nasdaq GlobeNewswire

Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

30 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

25 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Veru Announces Date of 2024 Annual Meeting of Shareholders

01 Apr 2024 16:05:00 By Nasdaq GlobeNewswire

Veru Reschedules Annual Meeting of Shareholders

22 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

12 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

27 Feb 2024 19:15:00 By Nasdaq GlobeNewswire

Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

20 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Veru Reports Fiscal 2024 First Quarter Financial Highlights

08 Feb 2024 06:30:00 By Nasdaq GlobeNewswire

Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs

06 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

31 Jan 2024 08:30:00 By Nasdaq GlobeNewswire

Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024

25 Jan 2024 08:30:00 By Nasdaq GlobeNewswire

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss

08 Jan 2024 08:30:00 By Nasdaq GlobeNewswire

Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs

19 Dec 2023 08:30:00 By Nasdaq GlobeNewswire

Veru Announces Pricing of Public Offering of Common Stock

14 Dec 2023 09:00:00 By Nasdaq GlobeNewswire

Veru Announces Proposed Public Offering of Common Stock

13 Dec 2023 16:01:28 By Nasdaq GlobeNewswire

Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasing Fat Loss in a Phase 2b Obesity Clinical Study

04 Oct 2023 08:30:00 By Nasdaq GlobeNewswire

Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)

26 Sep 2023 08:30:00 By Nasdaq GlobeNewswire

Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023

20 Sep 2023 08:30:00 By Nasdaq GlobeNewswire

Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer

11 Sep 2023 07:00:00 By Nasdaq GlobeNewswire